BHVN
Biohaven Ltd.
1W: -6.6%
1M: -21.4%
3M: -17.7%
YTD: -17.4%
1Y: -68.9%
3Y: -35.2%
$8.93
-0.03 (-0.33%)
After Hours: $8.37 (-0.56, -6.27%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$46.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$945.4M
52W Range7.48-31.18
Volume6,120,142
Avg Volume2,709,432
Beta3.53
Dividend—
Analyst Ratings
Company Info
CEOVladimir Coric
Employees256
SectorHealthcare
IndustryBiotechnology
IPO Date2022-09-23
Websitebiohaven.com
215 Church Street
New Haven, CT 06510
US
New Haven, CT 06510
US
203 404 0410
About Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Latest News
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
What's Going On With Biohaven Stock On Monday?
Biohaven Non-GAAP EPS of -$0.90 beats by $0.06
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mehta Kishan | G-Gift | 17,342 | — | 2026-03-17 |
| Mehta Kishan | G-Gift | 17,342 | — | 2026-03-17 |
| Car Bruce | A-Award | 175,000 | $11.52 | 2026-02-27 |
| Coric Vlad | A-Award | 550,000 | $11.52 | 2026-02-27 |
| Buten Matthew | A-Award | 175,000 | $11.52 | 2026-02-27 |